4.355
price up icon2.35%   0.105
 
loading
Omeros Corporation stock is traded at $4.355, with a volume of 130.57K. It is up +2.35% in the last 24 hours and up +15.38% over the past month. Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$4.25
Open:
$4.22
24h Volume:
130.57K
Relative Volume:
0.51
Market Cap:
$251.49M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
6.8047
EPS:
0.64
Net Cash Flow:
$74.30M
1W Performance:
+1.40%
1M Performance:
+15.38%
6M Performance:
+16.62%
1Y Performance:
+239.84%
1-Day Range:
Value
$4.22
$4.37
1-Week Range:
Value
$4.01
$4.37
52-Week Range:
Value
$1.13
$5.68

Omeros Corporation Stock (OMER) Company Profile

Name
Name
Omeros Corporation
Name
Phone
206-676-5000
Name
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Name
Employee
198
Name
Twitter
@OmerosCorp
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
OMER's Discussions on Twitter

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-08-22 Downgrade UBS Buy → Neutral
Nov-08-22 Downgrade BofA Securities Neutral → Underperform
Jun-08-22 Downgrade BofA Securities Buy → Neutral
Oct-08-21 Downgrade JP Morgan Neutral → Underweight
Oct-01-21 Downgrade Maxim Group Buy → Hold
Oct-01-21 Downgrade Wedbush Neutral → Underperform
Sep-27-21 Initiated JP Morgan Neutral
Feb-01-21 Initiated UBS Buy
Oct-20-20 Initiated BofA Securities Buy
Aug-21-20 Reiterated H.C. Wainwright Buy
Aug-14-20 Reiterated Maxim Group Buy
May-06-19 Initiated Cantor Fitzgerald Overweight
Jul-12-18 Initiated Seaport Global Securities Buy
Mar-23-18 Downgrade Wedbush Outperform → Neutral
Mar-05-18 Downgrade Needham Buy → Hold
Nov-08-17 Initiated H.C. Wainwright Buy
May-11-17 Downgrade Cantor Fitzgerald Buy → Neutral
Mar-17-17 Reiterated Maxim Group Buy
Mar-17-17 Reiterated Needham Buy
Nov-16-16 Reiterated Wedbush Outperform
Nov-10-16 Reiterated Needham Buy
Aug-10-16 Reiterated Maxim Group Buy
Jun-03-16 Initiated Cantor Fitzgerald Buy
Mar-02-16 Reiterated Needham Buy
Feb-29-16 Reiterated Wedbush Outperform
Nov-11-15 Reiterated Needham Buy
Aug-18-15 Reiterated WBB Securities Strong Buy
Aug-10-15 Initiated ROTH Capital Buy
View All

Omeros Corporation Stock (OMER) Latest News

pulisher
Oct 29, 2024

Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 29, 2024
pulisher
Oct 25, 2024

Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com

Oct 25, 2024
pulisher
Oct 24, 2024

OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire

Oct 24, 2024
pulisher
Oct 22, 2024

Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com

Oct 22, 2024
pulisher
Oct 21, 2024

Ischemia Reperfusion Injury Therapeutics Market Generated - openPR

Oct 21, 2024
pulisher
Oct 17, 2024

Omer Arbel Office unveils planned community for Washington State site - The Architect's Newspaper

Oct 17, 2024
pulisher
Oct 17, 2024

OMER (Omeros) Operating Margin % : 0.00% (As of Jun. 2024) - GuruFocus.com

Oct 17, 2024
pulisher
Oct 15, 2024

PDE Inhibitors Market: Report Trends and Future Forecast Until (2024-2034) - IndiaPolitics.com

Oct 15, 2024
pulisher
Oct 13, 2024

Metastatic Melanoma Drug Industry Size, Regional Demand, Trends and Forecast to (2024-2034) - Cineglit

Oct 13, 2024
pulisher
Oct 11, 2024

China Gastrointestinal Stromal Tumor (GIST) Drug Market Research Covers, Future Trends and Deep Analysis (2024-2034) – IndiaPolitics.com - IndiaPolitics.com

Oct 11, 2024
pulisher
Oct 10, 2024

Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech

Oct 10, 2024
pulisher
Oct 08, 2024

Mizrahi Tefahot lends Omer Adam's server farm co NIS 410m - Globes

Oct 08, 2024
pulisher
Oct 08, 2024

Mydriasis Treatment Market: Company Profiles, Segment - openPR

Oct 08, 2024
pulisher
Oct 08, 2024

Global PNH and aHUS Market Analysis 2024-2032: Trends, Drivers, Challenges, and Quantitative Insights - WICZ

Oct 08, 2024
pulisher
Oct 08, 2024

Gastrointestinal Stromal Tumor (GIST) Drug Market Strategies and Forecast Till, (2024-2034) - உங்கள் குரல்

Oct 08, 2024
pulisher
Oct 07, 2024

Nicotine Addiction Treatment Market Current Status and Future Prospects (2024-2029)-RTI International, Omeros Corporation, Heptares Therapeu – cineglit - Cineglit

Oct 07, 2024
pulisher
Oct 05, 2024

Omeros (NASDAQ:OMER) Stock Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Metastatic Melanoma Drug Market In-Depth Analysis, Business Forecast and Dynamics 2023 – (2024-2034) - KnowCasino

Oct 04, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR

Oct 03, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart

Oct 03, 2024
pulisher
Oct 03, 2024

OMER Stock Falls 5.35% Amid Mixed Institutional Ratings - GuruFocus.com

Oct 03, 2024
pulisher
Oct 01, 2024

Omeros (OMER) Shares Drop 5.04% Amid Financial Struggles - GuruFocus.com

Oct 01, 2024
pulisher
Oct 01, 2024

PNH and aHUS Market 2024 – Key Regions, Company Profile, Opportunity and Challenge 2032 | Omeros Corporation, RA Pharmaceuticals - 대구포스트

Oct 01, 2024
pulisher
Oct 01, 2024

Relieved Omer Riza wants to grab 'great opportunity' after overseeing first Cardiff City win - Wales Online

Oct 01, 2024
pulisher
Sep 26, 2024

Global Nicotine Replacement Therapy Market is Predicted to - GlobeNewswire

Sep 26, 2024
pulisher
Sep 19, 2024

Orex Minerals Welcomes New CEO and Board Member - TipRanks

Sep 19, 2024
pulisher
Sep 19, 2024

SVP, Merchandising McLain Kevin sale 15,000 shares of Ollies Bargain Outlet Holdings Inc [OLLI] - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

Orrstown Financial Services (NASDAQ:ORRF) Reaches New 1-Year High at $36.65 - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Middleton & Co. Inc. MA Decreases Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Altria Group (NYSE:MO) Stock Price Down 0.3% - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

Meiji Yasuda Asset Management Co Ltd. Boosts Stock Position in Omnicom Group Inc. (NYSE:OMC) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Kendall Capital Management Has $7.22 Million Stake in Omnicom Group Inc. (NYSE:OMC) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Altrius Capital Management Inc Has $4.63 Million Holdings in Altria Group, Inc. (NYSE:MO) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

The growth track for OneMain Holdings Inc (OMF) has changed recently - SETE News

Sep 19, 2024
pulisher
Sep 19, 2024

Vanguard Personalized Indexing Management LLC Boosts Holdings in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Garner Asset Management Corp Grows Position in Old Republic International Co. (NYSE:ORI) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Axxcess Wealth Management LLC Trims Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Optimist Retirement Group LLC Cuts Stock Position in Omnicom Group Inc. (NYSE:OMC) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Market Insight: Omnicell, Inc. (OMCL)’s Notable Drop, Closing at 42.78 - The Dwinnex

Sep 19, 2024
pulisher
Sep 19, 2024

Optimist Retirement Group LLC Boosts Stock Position in Altria Group, Inc. (NYSE:MO) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Omnicom Group Inc. (NYSE:OMC) Position Increased by Sienna Gestion - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Meiji Yasuda Asset Management Co Ltd. Purchases 84,312 Shares of Altria Group, Inc. (NYSE:MO) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Oram Awards announces 2024 winners, celebrating women, trans, non-binary and gender expansive musicians - DJ Mag

Sep 19, 2024
pulisher
Sep 19, 2024

Omnicell, Inc.: Navigating a Turbulent Year, Up -23.68% from 52-Week Low - The InvestChronicle

Sep 19, 2024
pulisher
Sep 19, 2024

Bradley Foster & Sargent Inc. CT Reduces Stake in Omnicom Group Inc. (NYSE:OMC) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Omnicom Group (NYSE:OMC) Sets New 1-Year High at $102.75 - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Roper Technologies, Inc. (NYSE:ROP) Shares Sold by Inspire Investing LLC - Defense World

Sep 19, 2024

Omeros Corporation Stock (OMER) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Omeros Corporation Stock (OMER) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Demopulos Peter A MD
Director
Nov 15 '23
Buy
1.53
10,000
15,300
208,516
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):